Cargando…
Therapeutic Effects of a Novel Agonist of Peroxisome Proliferator-Activated Receptor Alpha for the Treatment of Diabetic Retinopathy
PURPOSE: Clinical studies have shown that peroxisome proliferator-activated receptor alpha (PPARα) agonist fenofibrate has therapeutic effects on diabetic retinopathy (DR). The purpose of this study was to identify a novel PPARα agonist and to evaluate its beneficial effects on DR. METHODS: The tran...
Autores principales: | Deng, Guotao, Moran, Elizabeth P., Cheng, Rui, Matlock, Greg, Zhou, Kelu, Moran, David, Chen, Danyang, Yu, Qiang, Ma, Jian-Xing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Association for Research in Vision and Ophthalmology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633008/ https://www.ncbi.nlm.nih.gov/pubmed/28979999 http://dx.doi.org/10.1167/iovs.16-21402 |
Ejemplares similares
-
SZN-413, a FZD4 Agonist, as a Potential Novel Therapeutic for the Treatment of Diabetic Retinopathy
por: Nguyen, Huy, et al.
Publicado: (2022) -
Alpha-Smooth Muscle Actin Expression and Parafoveal Blood Flow Pathways Are Altered in Preclinical Diabetic Retinopathy
por: An, Dong, et al.
Publicado: (2022) -
Targeted Blood Metabolomic Study on Retinopathy of Prematurity
por: Yang, Yuhang, et al.
Publicado: (2020) -
Metabolomics Analyses of Mouse Retinas in Oxygen-Induced Retinopathy
por: Zhou, Yedi, et al.
Publicado: (2021) -
Irisin Attenuates Pathological Neovascularization in Oxygen-Induced Retinopathy Mice
por: Zhang, Jieqiong, et al.
Publicado: (2022)